Stock Groups

Novartis more bullish on Cosentyx, Entresto sales as Q3 profit rises -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – The logo of Novartis, a Swiss pharmaceutical company is visible at its plant in Stein (Switzerland), October 23, 2017. REUTERS/Arnd Wiegmann

(Reuters] Novartis’s adjusted operating profit for the third quarter rose 10% due to an increase in peak sales of its most valuable pharmaceuticals.

Adjusted for specialty items, operating profit rose 10% to $4.47 Billion, driven by increased sales of Entresto and Entresto, which treat heart failure and arthritis.

Novartis announced Tuesday that it raised its peak sales guidance to Cosentyx at minimum $7 billion, and Entresto at least $5.0 million in a statement.

Disclaimer Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses caused by the data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]